Stem Cell Therapy for Ischemic Stroke In Munich, Germany
Stroke Stem Cell Treatment Improve Cognitive & Motor Skills
CBC Health provides experimental stem cell treatment for ischemic stroke survivors. Their experimental, therapeutic solution that is based on infusing ischemic stroke survivors with cord blood. Recent clinical trials have demonstrated that infusing cord blood can noticeably help ischemic stroke survivors improve cognitively and physically. CBC Health’s Ischemic Stroke Treatment is available in a specially designed day-clinic in Munich, Germany. The German healthcare system is noted for its high standards for efficiency, cleanliness, quality, and innovation.
What is Ischemic Stroke?
Ischemic stroke is the most common type of strokes, accounting for about 87% of all strokes. It occurs when the blood supply to part of your brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. Within minutes, brain cells begin to die, potentially resulting in devastating changes to muscles and nerves of the body with either isolated or complex impairments.
Cord Blood- Stem Cell Treatment for Stroke Recovery
Cord blood is the blood that remains in the placenta and umbilical cord after birth. Umbilical cord blood has several unique capabilities, such as being able to create all types of blood cells, stimulate regenerative processes in a brain damaged by an ischemic stroke, and serve as the core building blocks for dozens of regenerative therapies that are reshaping medicine today. Donated cord blood has been successfully used for 25 years to restore blood production in patients after chemotherapy. In the past decade, cord blood infusions have shown beneficial therapeutic effects for children diagnosed with cerebral palsy, and for children with cerebral strokes. In a recent clinical trial studying cerebral strokes in adults, patients registered significant therapeutic improvements, safely, when infused in the first ten days after the stroke event.
CBC Health Redefines Stem Cell Treatment for Stroke Patients
CBC Health uses cord blood that is readily available, tested and stored by Europe’s second-largest private cord blood repository, Cord Blood Center Group. The treatment should take a little over six hours and includes check-in, medical tests, and a relatively painless cord blood infusion which is followed by routine monitoring by the medical staff.
CBC Health provides cord blood components using allogeneic cord blood that can enhance nerve growth and other regenerative modalities in the brain that may include:
- Cell Replacement
- Neurotrophic Influence
- Immune Benef its
- Inflammatory Modulation in the Brain
Stroke Stem Cell Therapy- Treatment Overview
- Intravenous infusion of umbilical blood cells is a therapeutic procedure used in patients recovering from stroke.
- Umbilical cord blood is collected from placnta via the umbilical cord vein.
- To achieve an optimum therapeutic effect, a dose of 50 million cells per kg is required, and each infusion includes cord blood collected from 4 to 8 donors.
- The entire course of infusions is scheduled over two to three days, and after each infusion, the patient is monitored for several hours for any potential adverse reactions.
- In the majority of patients, cord blood infusions have resulted in mild improvement of cognitive and motor functions. These functional gains become noticeable within the first few weeks after the infusion and continue for the next 3 to 6 months.
- Adverse reactions to cord blood cell infusions are rare and generally mild.
Effect of Ischemic Stroke Treatment with Stem Cells
Cord blood infusion is not intended to be a replacement for standard therapy in the management of stroke, it is an additional therapeutic approach that may gain additional improvement of cognitive and motor functions. In patients undergoing cord blood therapy, there no need to temporarily discontinue other types of pharmaceutical or physical therapy. Intravenous cord blood cell infusions enhance the regenerative activity of brain cells in stroke patients. Clinical studies suggest that cord blood therapy is more effective when administrated soon after stroke occurs.
Patients begin to notice improvements within a few weeks after the infusion. The cord blood cells are eliminated from the patient’s body within 6 to 8 weeks; however, patients experience functional gains over the next 3 to 6 months, with sustained functional improvement. Achieved improvement is permanent, patients do not experience worsening of the achieved improvement.
Patients with severe functional impairment may experience little or no improvement, and patients with mild or minimal impairment experience moderate improvement. Clinical studies have shown that the most important factor influencing the therapeutic effect of cord blood infusion is cell dosage. In a recent clinical trial at Duke University on pediatric cerebral palsy patients (mostly induced by stroke), only patients who received more than 25 million cells per kg showed significant therapeutic effect (Kurtzberg et al; Blood 2015). In each of our cord blood infusions, the patient receives a standard of more than 50 million cells per kg.
Another study suggests that repeated cord blood infusions may lead to further functional improvements.
For more details about stroke treatment with stem cell therapy at the clinic, click the button below: